Navtika Desai, DO
Endocrinology, Diabetes & Metabolism · Hillsborough, NJNPI 1053376954
Payments from drug & device makers
Across 647 payments — averaging $629.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$279K
- Amgen$102K
- Astellas Pharma US Inc$24K
- Lilly USA, LLC$462
- Boehringer Ingelheim$269
- AstraZeneca$258
- plus $1K from 25 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 342 | $278,875 |
| Amgen(2 entities) | 138 | $101,969 |
| Astellas Pharma US Inc | 34 | $24,474 |
| Lilly USA, LLC | 32 | $462 |
| Boehringer Ingelheim | 17 | $269 |
| AstraZeneca(2 entities) | 14 | $258 |
| Bayer | 3 | $168 |
| Abbott | 3 | $155 |
| Sanofi-aventis U.S. LLC | 11 | $150 |
| AbbVie | 8 | $115 |
| IBSA Pharma Inc. | 9 | $111 |
| Merck | 6 | $72 |
| Senseonics, Incorporated | 4 | $61 |
| Dexcom, Inc. | 2 | $49 |
| Amneal Pharmaceuticals LLC | 3 | $40 |
| Viiv Healthcare Company | 2 | $36 |
| Johnson & Johnson | 2 | $28 |
| Shire North American Group Inc | 2 | $26 |
| Madrigal Pharmaceuticals | 1 | $24 |
| Valeritas, Inc. | 2 | $24 |
| Mannkind Corporation | 2 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $14 |
| Nalpropion Pharmaceuticals LLC | 1 | $13 |
| BD | 1 | $13 |
| Recordati_rare_diseases_inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
| Ipsen Biopharmaceuticals, Inc | 1 | $12 |
| Eisai Inc. | 1 | $11 |
| Vivus LLC | 1 | $11 |
How this compares
$407,517 in reported general payments places this provider in the 95th percentile of 367 endocrinology, diabetes & metabolism providers in New Jersey.
See all endocrinology, diabetes & metabolism providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other endocrinology, diabetes & metabolism in Hillsborough
- Barry GertzRahway$903K
- Nawras MakhsidaRandolph$882K
- Marc SandbergFlemington$567K
- Joanne WaldstreicherNew Brunswick$441K
- Gregory BaroneCherry Hill$433K
- Taher ModarressiPennington$414K
- Atara SchultzTeaneck$357K
- Anthony CannonTurnersville$296K
- Sunil AsnaniBrick$295K
- Stanislav GoykhmanLyndhurst$278K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.